- Home
- IRIX vs BIVI Comparison
IRIX vs BIVI Comparison
Compare IRIX & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRIX
- BIVI
- Stock Information
- Founded
- IRIX 1989
- BIVI 2013
- Country
- IRIX United States
- BIVI United States
- Employees
- IRIX N/A
- BIVI N/A
- Industry
- IRIX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- IRIX Health Care
- BIVI Health Care
- Exchange
- IRIX Nasdaq
- BIVI Nasdaq
- Market Cap
- IRIX 16.5M
- BIVI 15.1M
- IPO Year
- IRIX 1996
- BIVI N/A
- Fundamental
- Price
- IRIX $1.01
- BIVI $1.03
- Analyst Decision
- IRIX Hold
- BIVI Strong Buy
- Analyst Count
- IRIX 1
- BIVI 1
- Target Price
- IRIX $2.00
- BIVI $30.00
- AVG Volume (30 Days)
- IRIX 80.7K
- BIVI 865.3K
- Earning Date
- IRIX 05-13-2025
- BIVI 05-12-2025
- Dividend Yield
- IRIX N/A
- BIVI N/A
- EPS Growth
- IRIX N/A
- BIVI N/A
- EPS
- IRIX N/A
- BIVI N/A
- Revenue
- IRIX $48,804,000.00
- BIVI N/A
- Revenue This Year
- IRIX $9.61
- BIVI N/A
- Revenue Next Year
- IRIX N/A
- BIVI N/A
- P/E Ratio
- IRIX N/A
- BIVI N/A
- Revenue Growth
- IRIX N/A
- BIVI N/A
- 52 Week Low
- IRIX $0.78
- BIVI $0.62
- 52 Week High
- IRIX $3.25
- BIVI $7.50
- Technical
- Relative Strength Index (RSI)
- IRIX 40.50
- BIVI 50.60
- Support Level
- IRIX $0.98
- BIVI $1.00
- Resistance Level
- IRIX $1.19
- BIVI $1.29
- Average True Range (ATR)
- IRIX 0.06
- BIVI 0.14
- MACD
- IRIX -0.02
- BIVI 0.01
- Stochastic Oscillator
- IRIX 8.57
- BIVI 42.23
About IRIX IRIDEX Corporation
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.